Avadel Pharmaceuticals plc (AVDL) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Dublin, Ireland. Le PDG actuel est Gregory J. Divis Jr..
AVDL a date d'introduction en bourse 1996-06-07, 188 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $2.12B.
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
